Krsnaa Diagnostics Analyst Review May 2026
- May 27, 2026
- Posted by: Neeraj Pandey
- Category: News
This Krsnaa Diagnostics analyst review for May 2026 covers all critical data investors need for KRSNAA at Rs 553.85. Krsnaa Diagnostics is a radiology and pathology PPP diagnostics company. This Krsnaa Diagnostics analyst review analyses technical levels, business fundamentals, valuation, and key risks for KRSNAA through FY27.
Click Here – Get Free Investment Predictions
Krsnaa Diagnostics Analyst Review: Company Snapshot May 2026
Krsnaa Diagnostics operates government hospital diagnostic centres across Maharashtra, Punjab, and Rajasthan under public-private partnership models. The table below summarises key metrics for this Krsnaa Diagnostics analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | KRSNAA |
| Sector | Healthcare – Diagnostics |
| CMP (May 2026) | Rs 553.85 |
| 52 Week High | Rs 664.60 |
| 52 Week Low | Rs 443.10 |
| Market Cap | Rs 3500 Crore |
| Trailing P/E | 28x |
| Analyst Consensus Target | Rs 692.31 |
| Bull Case Target | Rs 858.47 |
| Bear Case Target | Rs 470.77 |
Analyst Insight: Krsnaa Diagnostics Analyst Review for FY27
Associate Director Kunal Singla suggests watching Krsnaa Diagnostics closely in May 2026. At Rs 553.85, Kunal Singla flags Healthcare – Diagnostics sector dynamics as the key driver for KRSNAA’s price action. Support is near Rs 451.96 and resistance near Rs 587.08. Kunal Singla’s perspective in this Krsnaa Diagnostics analyst review is not a buy recommendation.
Technical Analysis in This Krsnaa Diagnostics Analyst Review
This Krsnaa Diagnostics analyst review places KRSNAA at Rs 553.85 within its 52-week band of Rs 443.10 to Rs 664.60. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating KRSNAA.
The Krsnaa Diagnostics analyst review identifies support in the Rs 451.96 to Rs 526.16 range and resistance in the Rs 587.08 to Rs 623.08 zone. A sustained close above Rs 587.08 could signal momentum toward the analyst consensus target of Rs 692.31.
Screen the best stocks on the Univest Screener.
Support and Resistance in This Krsnaa Diagnostics Analyst Review
- Support Zone: Rs 451.96 to Rs 526.16 – this Krsnaa Diagnostics analyst review identifies this as a potential accumulation signal for KRSNAA.
- Resistance Zone: Rs 587.08 to Rs 623.08 – the Krsnaa Diagnostics analyst review flags a close above Rs 587.08 as a positive signal for KRSNAA.
- Consensus Target: Rs 692.31 is the base-case target in this Krsnaa Diagnostics analyst review.
Business Segments in This Krsnaa Diagnostics Analyst Review
Government Hospital Diagnostic PPP
This primary segment drives revenue and margin for Krsnaa Diagnostics, supporting the earnings trajectory toward Rs 692.31 in this Krsnaa Diagnostics analyst review.
Radiology and Pathology Services
This segment adds meaningful scale to Krsnaa Diagnostics’s model and is a key EPS contributor through FY27 as identified in this Krsnaa Diagnostics analyst review.
New PPP Tenders and State Expansion
This growth frontier is a potential re-rating catalyst for KRSNAA and a key element of this Krsnaa Diagnostics analyst review.
Valuation: Krsnaa Diagnostics Analyst Review Bull Bear Base Case
At Rs 553.85 and P/E of 28x, this Krsnaa Diagnostics analyst review sets three scenarios: bull case Rs 858.47, base case Rs 692.31, and bear case Rs 470.77.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 858.47 | Strong FY27 delivery and Healthcare – Diagnostics re-rating |
| Base Case | Rs 692.31 | Moderate growth per analyst consensus in this Krsnaa Diagnostics analyst review |
| Bear Case | Rs 470.77 | Earnings miss or macro headwinds for KRSNAA |
FY27 Outlook in This Krsnaa Diagnostics Analyst Review
This Krsnaa Diagnostics analyst review for FY27 is constructive provided KRSNAA delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Healthcare – Diagnostics indicators, RBI policy, and FII flow trends.
Key Risks in This Krsnaa Diagnostics Analyst Review
This Krsnaa Diagnostics analyst review identifies four key risks for KRSNAA: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Krsnaa Diagnostics Analyst Review Verdict May 2026
This Krsnaa Diagnostics analyst review concludes that KRSNAA at Rs 553.85 presents a defined risk-reward with consensus target Rs 692.31. The 52-week range of Rs 443.10 to Rs 664.60 provides further context. Use this Krsnaa Diagnostics analyst review as a research reference and consult a SEBI-registered advisor before investing in KRSNAA.
FAQs: Krsnaa Diagnostics Analyst Review 2026
What is the analyst target for Krsnaa Diagnostics in 2026?
The Krsnaa Diagnostics analyst review consensus target is Rs 692.31, bull case Rs 858.47, bear case Rs 470.77.
Is Krsnaa Diagnostics a good buy at Rs 553.85?
At Rs 553.85 with PE 28x and target Rs 692.31, this Krsnaa Diagnostics analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Krsnaa Diagnostics analyst review.
What is the 52-week high and low of Krsnaa Diagnostics?
52-week high is Rs 664.60 and 52-week low is Rs 443.10. This Krsnaa Diagnostics analyst review contextualises KRSNAA at Rs 553.85 within this range.
What are the key risks for Krsnaa Diagnostics?
Key risks in this Krsnaa Diagnostics analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Healthcare – Diagnostics sector.
Where can I track live data for Krsnaa Diagnostics?
Track Krsnaa Diagnostics’s live price on the Univest Screener to complement this Krsnaa Diagnostics analyst review with real-time data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
